|Security||MBII / Marrone Bio Innovations, Inc. (57165B106)|
|Institutional Owners||30 (4 N-Q Owners)|
|Institutional Shares||113,769,140 - 102.99% (ex. N-Q)|
|Institutional Value||$ 62,882,000 USD (ex. N-Q)|
Institutional Stock Ownership and Shareholders
Marrone Bio Innovations, Inc. (NASDAQ:MBII) has 30 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 113,769,140 shares.
Largest shareholders include
Ospraie Ag Science Llc, Waddell & Reed Financial Inc, Van Herk Investments B.v., Ardsley Advisory Partners, Primecap Management Co/ca/, Vanguard Group Inc, Marrone Pamela G, Geode Capital Management, Llc, BlackRock Inc., and Capital Planning Advisors, LLC.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/mbii"><img src="https://images.fintel.io/us-mbii-so.png" alt="MBII / Marrone Bio Innovations, Inc. Institutional Ownership"><a>
|Taylor, Cottrill, Erickson & Associates, Inc.||15,000||30|
|VANGUARD GROUP INC||473,032||1,045,047||120.93||521||2,090||301.15|
|GUGGENHEIM CAPITAL LLC||17,851||36|
|WADDELL & REED FINANCIAL INC||4,714,892||24,714,892||424.19||5,186||47,321||812.48|
|Primecap Odyssey Funds (see advisory)|
|Spark Investment Management LLC||13,400||0||-100.00||15||0||-100.00|
|Capital Planning Advisors, LLC||11,500||33,079||187.64||13||66||407.69|
|Azimuth Capital Management LLC||35,000||0||-100.00||40||0||-100.00|
|Virtu Financial LLC||20,446||0||-100.00||24||0||-100.00|
|Raymond James Financial Services Advisors, Inc.||11,061||11,061||0.00||12||22||83.33|
|Ospraie Ag Science Llc||61,333,334|
|Fidelity Concord Street Trust (see advisory)|
|UBS Group AG||3,916||2,801||-28.47||4||6||50.00|
|STATE STREET CORP||10,800||10,800||0.00||12||22||83.33|
|ARDSLEY ADVISORY PARTNERS||3,681,580||10,348,247||181.08||4,050||12,733||214.40|
|BANK OF AMERICA CORP /DE/||0||10,102||0||20|
|Ishares Trust (see advisory)|
|Laurel Wealth Advisors, Inc.||20,000||40|
|LADENBURG THALMANN FINANCIAL SERVICES INC||2,850||1,200||-57.89||3||2||-33.33|
|Genovese Burford & Brothers Wealth & Retirement Plan Management, LLC||3,200||3,200||0.00||4||6||50.00|
|Marrone Pamela G||854,885|
|BlueCrest Capital Management Ltd||12,428||25|
|A.R.T. Advisors, LLC||23,171||0||-100.00||26||0||-100.00|
|NORTHERN TRUST CORP||24,737||31,936||29.10||27||64||137.04|
|ROYAL BANK OF CANADA||14||0||-100.00||0||0|
|OGOREK ANTHONY JOSEPH /NY/ /ADV||300||300||0.00||0||0|
|Hanson McClain, Inc.||10,000||10,000||0.00||11||20||81.82|
|VAN HERK INVESTMENTS B.V.||12,477,481|
|GEODE CAPITAL MANAGEMENT, LLC||89,410||89,410||0.00||98||178||81.63|
|TWO SIGMA SECURITIES, LLC||11,088||0||-100.00||13||0||-100.00|
|Carroll Financial Associates, Inc.||2,000||4|
|Ivy Funds (see advisory)|
|PRIMECAP MANAGEMENT CO/CA/||2,625,600||2,625,600||0.00|
We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.
However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.
- We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( MBII / Marrone Bio Innovations, Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
- We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.
These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!
15h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
16h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
Related News Stories
Marrone Bio Innovations, Inc. (NASDAQ:MBII) Q1 2018 Results Conference Call May 10, 2018 4:30 AM ET (0-3)
Marrone Bio Innovations, Inc. (MBII - Free Report) logged a net loss of $2.9 million or 4 cents per share in first-quarter 2018, narrower than a loss of $7.6 million or 31 cents per share a year ago. Loss per share for the reported quarter was in line with the Zacks Consensus Estimate. The narrower year-over-year loss was mainly due to a gain on the conversion of debt. (383-0)
Recently, I had the chance to attend the MicroCap Conference in New York City; it's an event I always look forward to. With over 120 companies in attendance, there's ample opportunity to speak with management, sit in on multiple presentations, and learn about exciting new businesses… Ideas abound! I'm on the hunt for a captivating story, an exciting tale, and a great adventure in the Microcap lore. (47-1)
One stock that might be an intriguing choice for investors right now is Marrone Bio Innovations, Inc. (MBII - Free Report) . This is because this security in the Chemical - Diversified space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. (0-4)
U.S. stocks ended the quarter on a strong point, but the Dow Jones Industrial Average’s longest win streak in 20 years came to an end. The index gained 1.1% on the day, while the S&P 500 Index experienced a 1.4% increase and the Nasdaq Composite surged 1.6% by day’s end. (1-1)
as of ET
|CEO||Marrone Pamela G|